This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Accelrys, Inc.. Active years: 2004.
Company Filing History:
Years Active: 2004
Title: Paul Kirchhoff: Innovator in Binding Affinity Estimation
Introduction
Paul Kirchhoff is a notable inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of biochemistry, particularly in the estimation of binding affinity between ligands and receptors. His innovative work has implications for drug design and molecular interactions.
Latest Patents
Kirchhoff holds a patent titled "Methods and systems for estimating binding affinity." This patent outlines methods and systems for predicting the binding affinity between a ligand and a receptor. In one embodiment, the predicted binding affinity (pKj) is determined using a formula that incorporates various interaction energies. The formula is expressed as pKj = C0 + C1*vdW + C2*Att_pol + C3*(Att_pol*Att_pol + Rep_pol*Rep_pol). Here, vdW represents the van der Waals interaction energy, Att_pol denotes the surface area of the ligand forming complimentary polar interactions, and Rep_pol indicates the surface area of the ligand forming uncomplimentary polar interactions. Additionally, the patent describes an improved process for calculating linear interpolation of grid-based vdW energy, which enhances accuracy in estimating binding affinities.
Career Highlights
Kirchhoff is associated with Accelrys, Inc., where he applies his expertise in computational chemistry and molecular modeling. His work at the company has allowed him to contribute to advancements in the understanding of molecular interactions and binding affinities.
Collaborations
He has collaborated with notable colleagues, including Cherayathumadom M Venkatachalam and Xiaohui Jiang. These collaborations have further enriched his research and development efforts in the field.
Conclusion
Paul Kirchhoff's innovative work in estimating binding affinities has made a significant impact in the realm of biochemistry. His contributions continue to influence drug design and molecular interaction studies.